This Article Full Text Full Text (PDF) Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                            What's this?

Recent Developments in Medicare Coverage of Off-Label Cancer Therapies

	Overview

 
It is estimated that half of the uses of anticancer drugs can be considered "off-label"¹; this is to say, they are used for indications that are not included in the labeling approved by the US Food and Drug Administration. The Medicare program covers uses of off-label drugs used in anticancer regimens when those uses are supported by at least one of the designated drug compendia. If an off-label use is not included in one of these designated compendia, then Medicare contractors are permitted to rely on peer-reviewed research published in one of 26 specified journals. During the past 18 . . . [Click for More]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. McAneny, T. Marsland, and K. King News and Notes From the 2009 Carrier Advisory Committee Meeting: Medical Necessity, Off-Label Chemotherapy, and More J. Oncol. Pract, November 1, 2009; 5(6): 301 - 304. [Full Text] [PDF]